A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

A Phase 3b, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy

The primary objective of the study is to assess the efficacy and safety of the combination of apremilast plus topical therapies for the treatment of adults with plaque psoriasis who have not achieved an adequate response with topicals alone.

Study Overview

• Status: Completed
• Conditions: Plaque Psoriasis
• Intervention / Treatment: Drug: Apremilast; Drug: Topical Therapy

Detailed Description

Participants will be enrolled at 28 sites in Japan. The study consists of 4 phases: a screening phase (4 weeks), an open-label combination therapy phase (16 weeks), an open-label combination therapy phase with optional topical reduction (16 weeks), and a post-treatment observational follow-up phase (4 weeks).

• Study Type: Interventional
• Enrollment (Actual): 152
• Phase: Phase 3

Contacts and Locations

Study Locations

• Germany
  • Erlangen, Germany, 91054
    • Research Site
• Japan
  • Asahikawa-shi, Hokkaido, Japan, 070-0810
    • Motomachi Dermatology Clinic
  • Asahikawa-shi, Hokkaido, Japan, 070-0810
    • Research Site
  • Bunkyo-ku, Japan, 113-8602
    • Nippon Medical School Hospital
  • Bunkyo-ku, Japan, 113-8655
    • The University of Tokyo Hospital
  • Chitose, Japan, 066-0021
    • Chitose Dermatology and Plastic, Reconstructive Surgery Clinic
  • Chitose, Japan, 066-0021
    • Research Site
  • Fukuoka-shi, Fukuoka, Japan, 814-0180
    • Fukuoka University Hospital
  • Fukuoka-shi, Fukuoka, Japan, 813-0044
    • Kiryu Dermatology Clinic
  • Fukuoka-shi, Fukuoka, Japan, 819-0167
    • Tomoko Matsuda dermatology Clinic
  • Fukutsu, Japan, 811-3217
    • Hino Dermatology Clinic
  • Fukutsu, Japan, 811-3217
    • Research Site
  • Kagoshima, Japan, 890-0055
    • Saruwatari Dermatology Clinic
  • Kagoshima, Japan, 890-0055
    • Research Site
  • Kamimashiki-gun, Japan, 861-3101
    • Noguchi Dermatorogy Clinic
  • Kamimashiki-gun, Japan, 861-3101
    • Research Site
  • Kitakyushu-city, Japan, 806-8501
    • Japan Community Health-care Organization Kyushu Hospital
  • Kitakyushu-city, Japan, 806-8501
    • Research Site
  • Koto-ku, Tokyo, Japan, 136-0074
    • Maruyama Dermatology Clinic
  • Koto-ku, Tokyo, Japan, 136-0074
    • Research Site
  • Minato-ku, Japan, 108-0014
    • Research Site
  • Minato-ku, Japan, 108-0014
    • Mita Dermatology Clinic
  • Morioka, Japan, 020-8505
    • Iwate Medical University Uchimaru Medical Center
  • Morioka, Japan, 020-8505
    • Research Site
  • Neyagawa, Japan, 572-0838
    • Research Site
  • Neyagawa, Japan, 572-0838
    • Yoshioka Dermatology Clinic
  • Obihiro, Japan, 080-0013
    • Takagi Dermatological Clinic
  • Osaka, Japan, 550-0006
    • Nippon Life Hospital
  • Osaka, Japan, 550-0006
    • Research Site
  • Sakai, Japan, 599-8272
    • Hino Clinic
  • Sakai, Japan, 599-8272
    • Research Site
  • Sakai-shi, Osaka, Japan, 593-8324
    • Kume Clinic
  • Sapporo, Japan, 003-0833
    • Kitagou Dermatology Clinic
  • Sapporo, Japan, 003-0833
    • Research Site
  • Sapporo, Japan, 060-0807
    • Kobayashi Skin Clinic
  • Sapporo, Japan, 060-0807
    • Research Site
  • Sapporo, Japan, 064-0807
    • Hosui Medical Clinic
  • Sapporo, Japan, 064-0807
    • Research Site
  • Sapporo-shi, Hokkaido, Japan, 060-0063
    • Sapporo Skin Clinic
  • Sapporo-shi, Hokkaido, Japan, 062-0042
    • Fukuzumi Dermatology Clinic
  • Shimotsuke, Japan, 329-0498
    • Jichi Medical University Hospital
  • Shimotsuke, Japan, 329-0498
    • Research Site
  • Shinagawa-ku, Tokyo, Japan, 141-8625
    • NTT Medical Center Tokyo
  • Shinjyuku-ku, Japan, 160-0023
    • Tokyo Medical University Hospital
  • Shinjyuku-ku, Japan, 160-0023
    • Research Site
  • Toyoake, Japan, 470-1192
    • Fujita Health University Hospital
  • Toyoake, Japan, 470-1192
    • Research Site
  • Fukuoka
    • Fukuoka-shi, Fukuoka, Japan, 814-0180
      • Research Site
    • Fukuoka-shi, Fukuoka, Fukuoka, Japan, 813-0044
      • Research Site
    • Fukuoka-shi, Fukuoka, Fukuoka, Japan, 819-0167
      • Research Site
  • Hokkaido
    • Obihiro-shi, Hokkaido, Japan, 080-0013
      • Research Site
    • Sapporo-shi, Hokkaido, Japan, 060-0063
      • Research Site
    • Sapporo-shi, Hokkaido, Japan, 062-0042
      • Research Site
  • Osaka
    • Sakai-shi, Osaka, Japan, 593-8324
      • Research Site
  • Tokyo
    • Bunkyo-ku, Tokyo, Japan, 113-8603
      • Research Site
    • Bunkyo-ku, Tokyo, Japan, 113-8655
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Subjects must satisfy the following criteria to be enrolled in the study:

1. Subject is ≥ 20 years of age at the time of signing the informed consent form (ICF) with plaque psoriasis.
2. Subject has understood and voluntarily signed an informed consent document prior to any study related assessments/procedures being conducted.
3. Subject is able to adhere to the study visit schedule and other protocol requirements.
4. Subject has chronic plaque psoriasis based on a diagnosis for at least 6 months prior to Baseline.
5. Subject has psoriasis with sPGA = 2 or 3 at screening and baseline.
6. Subject is currently treated for psoriasis with topical therapies only for at least 4 weeks prior to Baseline.
7. Subject has inadequate response to current topical therapy as per Investigator's discretion.
8. Subject is naïve to all biologic therapies for psoriasis vulgaris.

9. Subject must be in general good health (except for psoriasis) as judged by the Investigator, based on medical history, physical examination, and clinical laboratories.

   (NOTE: The definition of good health means a subject does not have uncontrolled significant co-morbid conditions).

10. Subjects that are females of childbearing potential (FCBP) must have a negative pregnancy test at Screening and Baseline. While on investigational product and for at least 28 days after taking the last dose of investigational product, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options described below:

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device; tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

1. Subject has any condition, including other inflammatory diseases or dermatologic conditions, which confounds the ability to interpret data from the study, including other types of psoriasis (ie, pustular, inverse, erythrodermic, or guttate), other than plaque psoriasis.
2. Subject has psoriatic arthritis that requires systemic therapy.
3. Subject has history of drug-induced psoriasis.
4. Subject has had prior treatment with biologic therapies for psoriasis.
5. Subject has used phototherapy or conventional systemic therapy for psoriasis within 8 weeks prior to baseline and during the study (including but not limited to cyclosporine, corticosteroids, methotrexate, oral retinoids, mycophenolate, thioguanine, hydroxyurea, sirolimus, sulfasalazine, azathioprine).
6. Subject has worsening of psoriasis indicated by an increase in sPGA of ≥ 1 from Screening to Baseline.
7. Subject cannot avoid excessive sun exposure or use of tanning booths for at least 8 weeks prior to Baseline and during the study.
8. Subject is currently enrolled in any other clinical trial involving an investigational product.
9. Subject has other than psoriasis, any clinically significant (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major disease that is currently uncontrolled.
10. Subject has malignancy or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years, except for treated (ie, cured) basal cell or squamous cell in situ skin carcinomas.
11. Subject has received a live vaccine within 3 months of baseline or plans to do so during study.
12. Subject is pregnant or breastfeeding (lactating) women.
13. Subject has bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed and the infection cured, at least 4 weeks prior to Screening and no new or recurrent infections prior to the Baseline Visit.
14. Subject is hepatitis B surface antigen positive or hepatitis B core antibody positive at screening.
15. Subject is positive for antibodies to hepatitis C at screening.
16. Subject has any condition, including the presence of laboratory abnormalities, which would place the subject at unacceptable risk if he/she were to participate in the study.
17. Subject has prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and enrollment, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.
18. Subject has active substance abuse or a history of substance abuse within 6 months prior to signing the informed consent.
19. Subject has prior treatment with apremilast or participation in a clinical study involving apremilast.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Apremilast; After a 5-day titration, participants received 30 mg apremilast tablets orally twice daily (BID) for up to 32 weeks in addition to their existing topical therapy. At week 16 participants were permitted to decrease their use of topical therapy at their own discretion under the direction of their physician.	Drug: Apremilast; Tablets for oral administration; Other Names: CC-10004; Otezla®; Drug: Topical Therapy; Participants continued to use their existing topical treatment for psoriasis for the first 16 weeks. After 16 weeks, participants could decrease the use of topical therapy at their discretion under the direction of their physician.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16	The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale, ranging from 0 (clear) to 4 (severe). The National Psoriasis Foundation Psoriasis Score version of a static PGA is calculated by averaging the total body erythema, induration, and desquamation scores. The overall scores are as follows: 0 = Clear; = Almost Clear;; = Mild;; = Moderate;; = Severe. The percentage of participants with a sPGA response was estimated using a multiple imputation method from 100 imputed data sets.	Week 16

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 32	The sPGA is an assessment by the Investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale, ranging from 0 (clear) to 4 (severe). The National Psoriasis Foundation Psoriasis Score version of a static PGA is calculated by averaging the total body erythema, induration, and desquamation scores. The overall scores are as follows: 0 = Clear; = Almost Clear;; = Mild;; = Moderate;; = Severe.	Week 32
Percentage of Participants Who Achieved a Scalp Physicians Global Assessment (ScPGA) Score of Clear (0) or Almost Clear (1) at Weeks 16 and 32	The ScPGA assesses scalp involvement of psoriasis based on scalp plaque elevation, scaling, and erythema. The 5-point ScPGA scale ranges from 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), to 4 (severe).	Weeks 16 and 32
Change From Baseline in Percentage of BSA Affected by Psoriasis at Weeks 16 and 32	The overall body surface area affected by psoriasis was estimated based on the palm area of the participant's hand, which equates to approximately 1% of total body surface area. BSA affected by psoriasis is expressed as a percentage of total body surface area. A negative change from baseline indicates improvement.	Baseline and weeks 16 and 32
Percent Change From Baseline in Pruritus Visual Analog Scale (VAS) at Weeks 2, 16, and 32	Participants were asked to indicate how much itch they have had due to psoriasis in the past week by placing a vertical stroke on a 100 mm line on which the left-hand boundary (0 mm) represented no itch, and the right-hand boundary (100 mm) represented worst itch imaginable. The distance from the mark to the left-hand boundary was recorded. A negative change from baseline indicates improvement.	Baseline and weeks 2, 16, and 32
Mean Change From Baseline in Shiratori's Pruritus Severity Score at Weeks 2, 16, and 32	Shiratori's Pruritus Severity Score is a pruritus (itchiness) severity assessment tool used in Japan. Daytime and nighttime pruritus were evaluated and scored separately. Daytime pruritus was rated on a five-grade scale: 0 (absent), 1 (endurable without scratching; minimal), 2 (subsides with slight scratching; mild), 3 (subsides with considerable scratching; moderate), or 4 (not subsiding with scratching, which prompts repeated scratching; severe). Nighttime pruritus was rated on a five-grade scale: 0 (absent), 1 (slight itching at bedtime but not causing intentional scratching; no difficulty sleeping because of pruritus), 2 (slight itching that subsides with scratching; no difficulty sleeping because of pruritus), 3 (difficulty sleeping because of pruritus that resolves with scratching; unconscious scratching occurs during sleep), or 4 (severe difficulty sleeping due to pruritus; frequent scratching that worsens pruritus). A negative change from baseline indicates improvement.	Baseline and weeks 2, 16, and 32
Percentage of Participants Who Achieved a ≥ 50% Reduction From Baseline in NAPSI Score (NAPSI-50) at Weeks 16 and 32 Among Participants With NAPSI ≥ 1 at Baseline	One target thumb nail or fingernail representing the worst nail psoriasis involvement was selected for assessment at Baseline. The nail matrix was assessed for presence of any of the nail matrix features (pitting, leukonychia red spots in the lunula, crumbling) graded on a scale of 0 (none) to 4 (present in all 4 quadrants). The nail bed was assessed for the presence of any nail bed features (onycholysis, splinter hemorrhages, subungual hyperkeratosis, "oil drop" (salmon patch dyschroma) on a scale from 0 (none) to 4 (present in all quadrants). The sum of the nail matrix and nail bed scores is the total score and ranges from 0 to 8 (worst).	Weeks 16 and 32
Change From Baseline in Dermatology Life Quality Index (DLQI) at Weeks 16 and 32	The DLQI questionnaire asks participants to evaluate the degree that psoriasis has affected their quality of life in the last week, and includes the following parameters: symptoms and feelings, daily activities, leisure activities, work or school activities, personal relationships and treatment related feelings. Participants answer 10 questions on a scale from 0 (not at all) to 3 (very much), except for Question 7, which first asks whether the participant's skin prevented them from working or studying (Yes (score = 3) or No (score = 0), then If "No", the participant is asked how much their skin was a problem at work or studying over the last week, with responses from 0 (not at all), 1 (a little), or 2 (a lot). The DLQI total score ranges from 0 to 30, with 30 corresponding to the worst quality of life, and 0 corresponding to the best. A negative change from baseline indicates improvement.	Baseline and weeks 16 and 32
Percent Change From Baseline in Psoriasis Area and Severity Index (PASI) Score at Weeks 16 and 32	The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity. A negative change from baseline indicates improvement.	Baseline and weeks 16 and 32
Percentage of Participants Who Achieved ≥ 75% Reduction From Baseline in PASI Score (PASI-75)	The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.	Weeks 16 and 32
Percentage of Participants Who Achieved ≥ 50% Reduction From Baseline in PASI Score (PASI-50)	The PASI is a measure of psoriatic disease severity taking into account qualitative lesion characteristics (erythema, thickness, and scaling) and degree of skin surface area involvement on defined anatomical regions. The PASI scores range from 0 to 72, with higher scores reflecting greater disease severity.	Weeks 16 and 32
Treatment Satisfaction Questionnaire for Medication (TSQM) Sub-domain Scores	The Treatment Satisfaction Questionnaire for Medication (TSQM) version II is a self-administered instrument to understand a participant's satisfaction on current therapy. The TSQM comprises 11 items across 4 domains focusing on effectiveness (Item 1 and 2), side effects (Item 4 to 6), convenience (Item 7 to 9), and global satisfaction (Item 10 and 11). With the exception of Item 3 (experience any side effects; yes or no), all items have five or seven responses. Item scores are summed to give four domain scores, which are in turn transformed to a scale from 0 (extremely dissatisfied) to 100 (extremely satisfied).	Baseline and weeks 16 and 32
Percentage of Participants Who Achieved a Patient Benefit Index (PBI) Score ≥ 1 at Weeks 16 and 32	The Patient Benefit Index (PBI) is used to assess patient-relevant benefits of psoriasis treatment as a function of the most important needs identified by the participant before the start of treatment. Participants were asked to assess the benefits of treatment by completing the Patient Benefit Questionnaire (PBQ), which consists of 25 treatment goal statements scored from 0 (not at all) to 4 (very). The PBI is calculated for each participant by weighing the achievement values of each statement by their importance to the individual patient as assessed prior to the start of treatment. The PBI ranges from 0 (no benefit) to 4 (maximum benefit).	Weeks 16 and 32
Number of Participants With Treatment-emergent Adverse Events (TEAEs)	The Investigator assessed the severity/intensity of each adverse event as: Mild (asymptomatic or mild symptoms; intervention not indicated; activities of daily life (ADLs) minimally or not affected); Moderate (symptom(s) cause moderate discomfort; local or noninvasive intervention indicated; more than minimal interference with ADLs but able to carry out daily social and functional activities; drug therapy may be required); Severe (symptoms causing severe discomfort/pain; symptoms requiring medical/surgical attention/intervention; interference with ADLs including inability to perform daily social and functional activities; drug therapy required). A serious adverse event is any AE occurring at any dose that: Resulted in death;; Was life-threatening;; Required inpatient hospitalization or prolongation of existing hospitalization;; Resulted in persistent or significant disability/incapacity;; Was a congenital anomaly/birth defect;; Constituted an important medical event.	From first dose of study drug until at least 28 days after last dose; up to 36 weeks.

Collaborators and Investigators

• Sponsor: Amgen

Publications and helpful links

General Publications

• Okubo Y, Takahashi H, Hino R, Endo K, Kikuchi S, Ozeki Y, Nakamura T, Paris M, Abe M. Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study. Dermatol Ther (Heidelb). 2022 Jun;12(6):1469-1480. doi: 10.1007/s13555-022-00747-5. Epub 2022 Jun 11.

Helpful Links

• AmgenTrials clinical trials website

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 17, 2019
• Primary Completion (ACTUAL): May 8, 2020
• Study Completion (ACTUAL): September 25, 2020

Study Registration Dates

• First Submitted: April 25, 2019
• First Submitted That Met QC Criteria: April 25, 2019
• First Posted (ACTUAL): April 29, 2019

Study Record Updates

• Last Update Posted (ACTUAL): January 20, 2022
• Last Update Submitted That Met QC Criteria: December 20, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Skin Diseases, Papulosquamous; Psoriasis; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Phosphodiesterase Inhibitors; Phosphodiesterase 4 Inhibitors; Apremilast
• Other Study ID Numbers: CC-10004-PSOR-023; U1111-1230-7468 (REGISTRY: WHO); 20200062 (OTHER: Amgen Study ID)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
• IPD Sharing Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• IPD Sharing Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes